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Coxiella burnetii is an intracellular, zoonotic pathogen that is the causative agent of
Q fever. Infection most frequently occurs after inhalation of contaminated aerosols,
which can lead to acute, self-limiting febrile illness or more serve chronic infections
such as hepatitis or endocarditis. Macrophages are the principal target cells during
infection where C. burnetii resides and replicates within a unique phagolysosome-like
compartment, the Coxiella-containing vacuole (CCV). The first virulence determinant
described as necessary for infection was full-length lipopolysaccarride (LPS);
spontaneous rough mutants (phase II) arise after passage in immuno-incompetent hosts.
Phase II C. burnetii are attenuated in immuno-competent animals, but are fully capable
of infecting a variety of host cells in vitro. A clonal strain of the Nine Mile isolate (RSA439,
clone 4), has a 26 KDa chromosomal deletion that includes LPS biosynthetic genes
and is uniquely approved for use in BL2/ABL2 conditions. With the advances of axenic
media and genetic tools for C. burnetii research, the characterization of novel virulence
determinants is ongoing and almost exclusively performed using this attenuated clone.
A major problem with predicting essential virulence loci with RSA439 is that, although
some cell-autonomous phenotypes can be assessed in tissue culture, no animal model
for assessing pathogenesis has been defined. Here we describe the use of SCID mice for
predicting virulence factors of C. burnetii, in either independent or competitive infections.
We propose that this model allows for the identification of mutations that are competent
for intracellular replication in vitro, but attenuated for growth in vivo and predict essential
innate immune responses modulated by the pathogen during infection as a central
pathogenic strategy.
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INTRODUCTION
Q fever is a zoonotic disease caused by the Gram-negative bacterium Coxiella burnetii, which most
commonly causes asymptomatic or acute febrile illness but can lead to serious chronic infections
including endocarditis in humans (van Schaik et al., 2013). The mechanism of transmission is
usually inhalation of contaminated aerosols shed from domestic animals (Maurin and Raoult,
1999). The most common animal reservoirs associated with human infection are ruminants,
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mainly goats and sheep, which contributed to the large
outbreak recorded in the Netherlands from 2007 to 2009 (van
der Hoek et al., 2012; Brom et al., 2015). After inhalation,
C. burnetii becomes an intracellular bacterium that invades
and proliferates preferentially within (alveolar) macrophages
(Khavkin and Tabibzadeh, 1988; Graham et al., 2013). Invasion
of macrophages is through a passive mechanism after which the
C. burnetii vacuole traffics through the default endocytic pathway
ultimately to a phagolysosome-like compartment termed the
CCV (Baca et al., 1993; Howe et al., 2010; van Schaik et al.,
2013). This compartment becomes highly fusogenic and expands
concomitant with C. burnetii replication (Howe et al., 2003;
Coleman et al., 2004) while no apparent bactericidal mechanisms
are inhibited. C. burnetii manipulates a variety of host pathways
to create and maintain its unique intracellular replicative niche
including endolysosomal trafficking, secretion, autophagy, and
apoptosis (Larson et al., 2015).
It has been particularly challenging to define essential
host pathogen interactions with obligate intracellular bacterial
pathogens due to the difficulty of culturing them outside of
the host. Therefore, understanding virulence determinants of
these pathogens has relied on indirect assays. These difficulties
have contributed to a lag in progress in defining the pathogenic
mechanisms of obligate intracellular bacteria compared to
their facultative counterparts. Until recently, the only defined
C. burnetii virulence factor was full-length lipopolysaccarride
(LPS). Serial passage in vitro of virulent phase I C. burnetii causes
a shift to avirulent phase II LPS variants, a phenomenon that
is reminiscent of the smooth-to-rough LPS transition common
to many enterobacteria (Stoker and Fiset, 1956). This shift from
phase I to phase II LPS is most often defined by an irreversible
switch characterized by a large chromosomal deletion (Hoover
et al., 2002; Beare et al., 2006). Virulence studies using phase I
and phase II C. burnetii suggest the loss of virulence is due to
the binding of C3 to phase II, but not phase I organisms (Moos
and Hackstadt, 1987). The observation that phase II C. burnetii
is less virulent due to the loss of LPS, as a consequence of a
permanent 26 KDa chromosomal deletion, led to the exclusion
of one clonal derivative from Select Agent designation. Nine Mile
II (NMII) RSA439 is approved for use under Biosafety Level 2
(BL2) conditions as compared to the virulent Nine Mile I (NMI)
RSA493, which requires Biosafety (Select Agent) Level 3 (BSL3)
containment. All C. burnetii were strictly obligate intracellular
bacteria in the research laboratory until an axenic medium,
along with specific growth conditions that allow cultivation of
the bacteria outside of host cells, was established (Omsland
et al., 2009). As a result of this advance, C. burnetii is now a
genetically tractable organism, and its virulence can be more
directly assessed.
The application of axenic growth conditions led to the
development of various genetic tools including stable plasmid
vectors allowing the expression of tagged recombinant proteins
byC. burnetii, aHimar1 transposon for randommutagenesis, and
site-specific mutagenesis strategies (Beare et al., 2011b; Omsland
et al., 2011). These innovations have significantly advanced the
field and resulted in the identification of several novel virulence
factors that are essential for intracellular growth (Beare et al.,
2011a, 2014; Carey et al., 2011; Weber et al., 2013; Martinez et al.,
2014). The ease of working with the BL2 isolate, coupled with the
observation that NMII is comparable to NMI for invasion and
replication in a variety of cell types, has led to the description
of novel virulence factors using these genetic tools exclusively
in the phase II isolate (Howe et al., 2010). Several laboratories
have created Himar1 transposon mutant libraries in NMII as
a screening tool to identify novel virulence factors. The use of
the C. burnetii-adapted Himar1 transposon was instrumental
in characterizing the Type IVB secretion system (T4SS) as
an essential virulence factor (Beare et al., 2011a; Carey et al.,
2011). Following the observation that the T4SS is required for
intracellular replication came descriptions of a growing list of
essential secreted effectors, including several of the Cir (Weber
et al., 2013), Cvp (Larson et al., 2013, 2015; Martinez et al.,
2014), and Ank effectors (Martinez et al., 2014). Other novel
C. burnetii virulence factors that are T4SS-independent have been
identified using transposon mutagenesis, including the invasin,
OmpA, which is required for invasion of epithelial cells but not
macrophages (Martinez et al., 2014). Therefore, the ability to
mutate C. burnetii has been instrumental in the identification of
genes that are required for uptake and replication in host cells,
but continued expansion of these virulence factors will certainly
depend on the sensitivity of the screening methods.
Another roadblock in this research field has been the lack of
animal models for studying virulence using NMII C. burnetii
mutants. The Galleria mellonella moth model has been applied
to identifying essential virulence genes such as the Dot/Icm
T4SS, and although this model is an excellent choice for high-
throughput studies, it lacks the ability to fully mimic the
innate immune responses encountered within a mammalian host
(Norville et al., 2014). The immune system of G. mellonella
consists of the cellular and humoral responses. The cellular
response is mediated by hemocytes and involves responses
such as phagocytosis, encapsulation, and clotting. Whereas,
the humoral response is mediated by opsonins that recognize
conserved bacterial products similar to pattern recognition
receptors (PRRs) of mammals, antimicrobial peptides, and
melanization (Tsai et al., 2016). Therefore, G. mellonella has
some components that are similar to mammalian innate immune
responses. However, the genome is not fully sequenced and
there are no methods for creating mutants in G. mellonella, and
therefore analysis of host-pathogen interactions at the molecular
level is not currently possible. In addition, like Drosophila,
G. mellonella appears to lack NOD-like receptors (NLRs) and
therefore is unable to sense certain intracellular threats (Davis
et al., 2011). This may account for the similar virulence of
wild-type Legionella pneumophila and ∆flaA in G. mellonella as
opposed to what is seen in C57BL/6 mice, where activation of
Naip5/Ipaf by flagella induces a caspase-1 dependent response.
As a consequence, ∆flaA mutants replicate to higher numbers
than wild-type L. pneumophila in a mouse pulmonary model of
infection (Harding et al., 2013). With the recent description of
the C. burnetii effector IcaA, which dampens a non-canonical
inflammasome-specific response by inhibiting caspase 11, it will
be especially important to employ tractable animal models to
validate the contribution of this effector to pathogenesis in vivo
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and discover other mechanisms by which C. burnetii modulates
host immune responses (Cunha et al., 2015).
Here, we present a SCID mouse model of C. burnetii infection
that we have used to screen the virulence potential of NMII
Himar1 transposon mutants. The SCID model was used to
determine that CirA is required for virulence in vivo, which
was the first application of this assay (Weber et al., 2016). This
report describes the validation of the model and its utility in
comparing virulence between NMII strains. An advantage of
this model is that it may be used under ABL2 conditions with
FIGURE 1 | Time course of intra-peritoneal challenge of C57/BL6 mice with NMII and the specific IFN-γ CD4+ T-cells response. (A) Splenomegaly
calculated as spleen weight as a percentage of total body weight at the time of necropsy on days 3, 7, 14, and 28 after infection with 1 x 106 GE of NMII, or at 3 days
after infection with 1 x 106 with dotA NMII mutant. (B) IFN-γ ELIspot was performed using CD4+ T cells purified from NMII infected spleens at 28 days after infection
and stimulated with naïve splenocytes loaded with formalin-fixed NMI (WCVI), or stimulated with concavalin A (ConA). Data are represented as spot forming cells per 1
× 106 cells after deduction of the background spots counted in un-stimulated control wells. (C) Genome equivalents calculated using TaqMan real-time PCR with
DNA purified from infected lungs from 5 mice on days 3, 7, 14, and 28 days after infection with 1 × 106 GE of NMII or at 3 days after infection for 1 × 106 with dotA
NMII mutant. (D) Genome equivalents calculated using TaqMan real-time PCR with DNA purified from infected spleens from 5 mice on days 3, 7, 14, and 28 days after
infection with 1 × 106 GE of NMII or at 3 days after infection for 1 × 106 with dotA NMII mutant. For all panels, error bars represent standard deviations from the mean.
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NMII mutants and therefore does not require creation of site-
specific mutants in NMI to test in vivo phenotypes. Our data
demonstrate that intra-peritoneal (IP) infections in SCID mice
are dose-dependent, resulting in splenomegaly characteristic of
NMI infections in wild-type mice. In addition, organisms can
be found in the spleens, lungs, and hearts of infected animals,
showing the potential to identify dissemination defects. This
model can also be used to determine relative fitness of a mutant
strain in comparison to wild-type C. burnetii via single infection
and in competitive infection assays.
MATERIALS AND METHODS
Bacterial Strains, Media, and Growth
Conditions
Coxiella burnetii RSA439 NMII (clone 4) was used as the parent
strain for this study. All mutants used in this study were created
using pKM225 containing theHimar1 transposon and confirmed
using rescue cloning as described (Weber et al., 2013) or plTR-
CAT-ColE1-P311-GFP and pUCP19::Himar1C9 and confirmed
using single primer colony PCR as described (Beare et al., 2009;
Martinez et al., 2014). Coxiella burnetii wild-type and mutant
strains were grown in ACCM-2 at pH 4.75 from Sunrise Science
Products (San Diego, CA, USA) for 7 days at 37◦C with 5% CO2
and 2.5% O2. Cultures were then centrifuged at 15,000 × g for
20min and re-suspended in PBS pH 7.4. Genome equivalents
(GE) for each bacterial stock were determined using quantitative
real-time PCR as described below.
Mouse Challenge Studies
Both SCID (C.B-17/LcrHsd-Prkdcscid) and C57BL6
(C57BL/6NHsd) mice were purchased from Envigo
(Indianapolis, IN, USA) and housed in the TAMHSC animal
facility. All animal procedures were done in compliance
with Texas A&M University IACUC (AUP#2014-0131 and
USAMRMC ACURO (CB-2012-28). Six to eight week old female
mice (SCID or C57BL/6) were infected with 105–108 of the
NMII strain specified in 100 µL PBS pH 7.4 via IP injection or
through intra-tracheal (IT) injection using a Biolite intubation
system (Braintree Scientific Inc., Braintree, MA, USA) and
MicroSprayer R© Aerosolizer (Penn-Century Inc.). Inoculum
concentrations were confirmed by serial dilution spot plating as
FIGURE 2 | Infection of SCID mice with NMII is dose-responsive after intra-peritoneal challenge. (A) Genome equivalents per organ were calculated using
TaqMan real-time PCR with DNA purified from infected spleens of 3 mice on days 10 or 14 after intra-peritoneal challenge with 1 × 105 to 1 × 108 GE of NMII. The
R2 (goodness-of-fit) for the linear regression was 0.86 calculated using Prism GraphPad software. (B) Genome equivalents per organ were calculated using TaqMan
real-time PCR with DNA purified from infected lungs of 3 mice on days 10 or 14 after intra-peritoneal challenge with 1 × 105 to 1 × 108 GE of NMII. (C) Genome
equivalents per organ were calculated using TaqMan real-time PCR with DNA purified from infected hearts of 3 mice on days 10 or 14 after intra-peritoneal challenge
with 1 × 105 to 1 × 108 GE of NMII (D) Splenomegaly calculated as spleen weight as a percentage of total body weight at the time of necropsy on days 10 or 14
after infection with 1 × 105 to 1 × 108 GE of NMII.
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described in Sandoz et al. (2016a) on ACCM-2 agarose with or
without chloramphenicol selection. For competitive infections,
SCID mice were challenged with a 1:1 GE mixture of NMII and
Himar1 transposon mutant, for a total of 106 bacteria per mouse.
Mouse Tissue Collection, Processing, and
DNA Purification
3, 7, 14, or 28 days post infection at necropsy the spleens
were removed and weighed to determine splenomegaly (spleen
weight/body weight). The lungs and hearts were also removed.
All organs were individually added to 1 mL PBS pH 7.4 and
homogenized using an Omni (TH) equipped with plastic tips
(Kennesaw, GA, USA). After homogenization 50µL of organ was
added to 450 µL tissue lysis buffer (Roche) containing 50 µL of
proteinase K and incubated at 55 degrees O/N. The following
day 50 uL of 10% SDS (w/v) was added and incubated at room
temperature for 1 h. Lysed tissue samples were then processed
using Roche High Pure PCR template preparation kit according
to manufacturer’s recommendations (Indianapolis, IN, USA).
Quantitative Real-Time PCR
DNA purified from infected organs was used as template for
TaqMan real time PCR using primers and probe for com1
(CBU_1910) (com1_L1: CGCGTTGTCTTCAAAGAACT;
com1_R1: GCGTCGTGGAAAGCATAATA; Probe: 5′FAM-
CGGCCAATCGCAATACGCTG-3′TAMRA) with NMII
genomic DNA serving as the standard (107–103 copies), or
primers and probe of IS1111 (IS1111_L1: GAATCAATAACG
TCCTTAACATCA; IS1111_R1: CCAATGAGGATTGTCAAC
GG; Probe: 5′FAM-TGATGAATGTCACCCACGCTCGCA-
3′TAMRA). For competitive infections, primers and probe
for Himar1 transposon (Himar1_L1: GAGATCAAGCAG
AGGCTGAA; Himar1_R1: CTTGGCCTTGTAGGTGGTCT;
Probe: 5′FAM-AGGACGGCGGCCACT ACGAC-3′TAMRA)
with genomic DNA from a C. burnetii Himar1 transposon
mutant serving as the standard (107–103 copies) to enumerate
mutant bacteria. 20 µL reactions were made up with ABI
TaqMan universal PCR mastermix and run on ABI StepOne Plus
machine. For competitive infections, genomes were quantified
using both the IS1111 (for total bacteria) and Himar1 (for
transposon mutants) probe and primer sets. The competitive
index (CI) for each infection was calculated by dividing the ratio
of mutant-to-wild type genomes in the output sample by that in
the inoculum.
ELIspot
At 28 days post-infection, spleens were removed from NMII-
infected mice or naïve control and placed in a 60mm culture
dish with 3mL of PBS + 1% BSA on ice. Seventy micron
sterile nylon mesh was placed onto the spleens and they were
mechanically disrupted using a syringe plunger. The spleen cells
were placed through another 70 micron nylon mesh filter into
15 mL conical tubes, which were then filled with 10mL PBS +
1% BSA and centrifuged at 500 × g for 5min. Naïve splenocytes
were resuspended in 1mL ACK buffer and incubated on ice
for 1 min, followed by addition of 10mL of PBS + 1% BSA
and centrifugation at 500 × g for 5min. Naïve splenocytes
were resuspended in 3mL PBS + 1% BSA and counted using
a hemocytometer and diluted to 1 × 106 cells/mL in RPMI
complete (RPMI supplemented with 10% FBS) and incubated
with 5 µg/mL formalin fixed NMI (WCVI) for 30min at 37
degrees 5% CO2. CD4+ T cells were isolated fromNMII-infected
splenocytes using Miltenyl Biotec CD4+ isolation kit according
to manufacturer’s recommendations (San Diego, CA, USA).
Isolated CD4+ cells were counted using a hemocytometer and
resuspended at 1 × 107 cells/mL in RPMI complete media. R&D
Systems Mouse IFN-γ ELIspot R© plates were treated according
to manufacturer’s recommendations and then 100 µL of CD4 +
T cells were added to wells in triplicate and either unstimulated,
stimulated with Concavalin A (Sigma) or antigen primed naïve
splenocytes, and incubated for 24 h at 37 ◦C in 5% CO2.
ELIspot plates were developed according to the manufacturer’s
recommendations and spots were counted using an Immunospot
S5 Micro reader from CTL (Cleveland, OH, USA).
RESULTS
Our first objective was to evaluate the utility of an immuno-
competent mouse to assess the suitability of predicting relative
virulence using NMII and an attenuated derivative of NMI after
time course IP challenge using both qPCR to assess genome
equivalents and spot plating to determine colonization. Mice
were infected with 1 × 106 genome equivalents (GE) IP of
either NMII or Himar1 dotA mutants and then culled at days
3, 7, 14, and 28 after infection. We saw no significant increase
in splenomegaly at any time after infection (Figure 1A). We
did, however, see significantly enlarged thymuses in all mice
at day 3 (data not shown) and proceeded to evaluate immune
FIGURE 3 | Gross Pathology of SCID mouse organs after
intra-peritoneal challenge. SCID mice were challenged with 1 × 108 GE or
PBS via intra-peritoneal route and sacrificed 10 days after challenge. Spleens
and livers were removed from challenged and control mice. Arrows indicate
spots of gross pathology on the livers of mice after challenge with NMII.
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response after challenge by IFN-γ ELIspot as a correlate of cell-
mediated response 28 days after challenge. We observed that
the mice do, in fact, mount a significant antigen specific CD4+
mediated immune response to IP challenge withC. burnetiiNMII
(Figure 1B). Although we did see evidence of steady state GEs
in the lungs and spleens at all days post challenge, there were
minimal or no viable bacteria as assessed by spot plating. Less
than 120 CFU were found in 7 and 14 day spleens (Figures 1C,D
and data not shown).We conclude that immune-competent mice
are not a feasible model for studying virulence of C. burnetii
NMII isolates.
A dose-response IP challenge was performed in SCID mice
with NMII. At 10–14 days post-challenge, genome equivalents
were detected in the spleens, lungs, hearts and livers of infected
mice (Figures 2A–C and data not shown). At higher doses
(107 and 108) gross pathology was observed on the livers, and
pericarditis was observed on the hearts of some of the mice
(Figure 3 and data not shown). Mice in the 108 challenge group
lost more than 20% of their body weight by day 10 and were
removed from the study based on animal welfare guidelines.
Increasing bacterial loads were found in all organs, and although
there was a slight plateau in the 108 group for spleens and
lungs, this is probably a result of these mice being removed
from the study 4 days before all other doses (Figures 2A–C and
data not shown). In addition, there was an increasing trend
in splenomegaly from 105 to 107 (Figures 2D, 3). We again
FIGURE 4 | Intra-peritoneal challenge of SCID mice can be used to test the virulence of NMII mutants. (A) Genome equivalents calculated using TaqMan
real-time PCR with DNA purified from infected spleens of 5 mice per group on day 14 after challenge with 1 × 106 GE equivalents of the strains shown. (B) Genome
equivalents calculated using TaqMan real-time PCR with DNA purified from infected lungs of 5 mice per group on day 14 after challenge with 1 × 106 GE equivalents
of the strains listed in the figure legend. (C) Splenomegaly calculated as spleen weight as a percentage of total body weight at the time of necropsy on day 14 after
infection with 1 × 106 GE equivalents of the strains listed in the figure legend. For all panels, the data was analyzed using One-way ANOVA followed by the Dunnett’s
multiple comparisons test against NMII with Prism GraphPad software and significance is displayed using * for P < 0.05, *** for P < 0.005, and **** for P < 0.0001.
Error bars represent standard deviations from the mean.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6 February 2017 | Volume 7 | Article 25
van Schaik et al. SCID Mouse Virulence Factors C. burnetii
speculate that the plateau in splenomegaly observed in the 107
challenge as compared to, the 108 challenge group was a result of
these animals being removed from the study prior to day 14. The
re-seeding of lungs, liver, and hearts may offer an opportunity to
look for dissemination or organ-specific virulence defects.
Based on the dose response studies, subsequent challenges
were performed at 1 × 106 GE per mouse, as the splenomegaly
observed was comparable to splenomegaly observed after NMI
challenge in wild-type mice at similar dose (Andoh et al., 2007).
Since steady state GEs were observed in wild-type mice after
NMII infection, even though there were few if any culturable
C. burnetii, the ability to detect heat-killed NMII was determined
after 14 days of infection in SCID mice (Figure 4A). The ability
of an intracellular replication-deficient mutant dotA as well as
several other transposon mutants that may have attenuated in
vivo phenotypes were compared to wild-type NMII (Figure 4A).
Splenomegaly was determined and GEs were enumerated in the
spleens and lungs of infected mice. There was no evidence of
splenomegaly for uninfected or animals challenged with heat-
killed NMII, and the GEs were below the limit of detection
in the spleens (<1000) (Figures 4A,C). Although there were
detectable GEs for dotA mutant in both lungs and spleens, they
were significantly reduced compared NMII (2 logs and 1 log
different, respectively; Figures 4A,B). In addition, there was no
detectable splenomegaly for the dotAmutant strain (Figure 4C).
We then tested Himar1 mutants that may have attenuated in
vivo phenotypes including cvpB (Martinez et al., 2016), ompA
(Martinez et al., 2014), and enhC (Sandoz et al., 2016b). Of
these mutants, cvpB and enhC were the most attenuated with
almost background (naïve/heat killed) levels of GEs in the
spleens (cvpB and enhC) and lungs (cvpB, EnhC was not assessed
for lung loads), while ompA had GEs in both spleens and
lungs but the lung load was significantly lower than that of
NMII (Figures 4A,B). In addition, there was no evidence of
splenomegaly for the cvpB and enhC mutants, but intermediate
splenomegaly for ompA (Figure 4C). We confirmed that the
ompAmutants detected in the spleens were viable by spot plating
and consistent with the GE proportions (data not shown). We
conclude that the IP challenge model using SCID mice is a
feasible model to test the virulence of NMIIHimar1mutants with
two distinct readouts: splenomegaly, as a pathologic correlate,
and GEs per organ, as a colonization correlate of disease.
We also tested the ability to perform competitive infections
with a Himar1 mutant that is predicted to have comparable
virulence to wild-type C. burnetii based on the insertion locus,
and dotA, which is attenuated relative to wild-type (Figure 4A).
The competitive index was determined after IP challenge with
a 1:1 ratio of mutant to wild-type strains (Figure 5). Consistent
with the above results, the dotA mutant was indeed found to
be less fit than wild-type NMII, with an average competitive
index (CI) of 0.216. The other Himar1 mutant that was tested
in the competitive infection assay, Tn::CB0206, was not found to
be attenuated, as it successfully competed with wild-type NMII
(average CI of 3.16). These results are consistent with our findings
that in independent infections, the GE and CFU numbers
recovered from spleens infected with the CB0206 mutant were
not significantly different from that of wild-type NMII with an
FIGURE 5 | Fitness of dotA and CB0206 Himar1 transposon mutants
relative to NMII Coxiella burnetii. The relative fitness of dotA and CB0206
mutants was compared to wild-type NMII in mixed infections in 5 mice per
group where NMII and mutant were inoculated into SCID mice IP in equal
proportions. The competitive index (CI) for each infection was calculated by
dividing the ratio of mutant-to-wild type genomes in the output sample by that
in the inoculum. A CI of 1 indicates the mutant strain has no loss of fitness
relative to wild-type bacteria. The data was analyzed using One-way ANOVA
followed by the Dunnett’s multiple comparisons test against NMII with Prism
GraphPad software and significance is displayed using * for P < 0.05. Error
bars represent standard deviations from the mean.
average of 2 × 107 and 9 × 107 respectively between mouse
groups.
Finally, since C. burnetii is most commonly transmitted to
humans via the respiratory route we evaluated the utility of
a potentially more physiologically relevant inoculation route,
intra-tracheal (IT) challenge, in the SCID mice. The inoculum
was assessed using spot-plating before and after aerosolization
with the microsprayer to confirm that the C. burnetii inoculated
into the lungs remain viable (Figure 6A). Mice were infected
(IT) with 1 × 106 GE and then culled at 5, 7, and 10 days after
challenge. Splenomegaly was assessed, and although there was a
trend from day 3 to 10 of a slight increase in splenomegaly, the
difference was not statistically significant, and does not resemble
the extensive splenomegaly observed in mice with IP NMI
challenge (Figure 6B). In addition, we observed only a modest
increase of C. burnetii genomes in the lungs and spleen over
the time period assessed post-infection (Figure 6C and data not
shown). Therefore, although infections lasting greater than 10
days may provide information about virulence, the IT challenge
was not a robust model for assessing virulence of NMII isolates.
DISCUSSION
Here we describe a SCID mouse model for testing C. burnetii
NMII mutants for virulence. We confirmed that wild-type mice
are not a suitable model for predicting the virulence of NMII
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FIGURE 6 | Large particle aerosolization (LPA) intra-tracheal challenge of SCID mice with NMII. (A) Colony forming units of NMII present in the inoculum
before and after aerosolizaiton with a MicroSprayer® Aerosolizer (Penn-Century Inc.) as determined by spot plating on ACCM-2. (B) Splenomegaly expressed as
spleen weight as a percentage of total body weight at the time of necropsy on days 5, 7, 10 after intra-tracheal challenge with 1 × 106 GE of NMII. (C) Genome
equivalents per organ were calculated using TaqMan real-time PCR with DNA purified from infected spleens of 5 mice per group on days 5, 7, and 10 after
intra-tracheal challenge with 1 × 106 GE of NMII. For all panels, error bars represent standard deviations from the mean.
strains, since no evidence of splenomegaly was observed and
only steady state GEs were found in both lungs and spleens.
However, the ability to detect NMII GE even 28 days after
challenge despite the fact that no viable bacteria were detected
based on spot-plating suggest that although NMII is not able to
cause productive infections in wild-type mice, it may be able to
persist in a viable but non-culturable state. Further evidence to
support this hypothesis is that GE from heat killed NMII in SCID
mice are not detectable after 14 days, therefore, the detection
of GE in wild-type mice even after 28 days suggests that these
bacteria are potentially still viable or would have been cleared
especially considering wild-type mice mount a specific CD4+ T-
cell response (Figure 1B). This observationmay have somemajor
implications for the ability of C. burnetii to persist within a host
for years to decades without causing disease.
SCID mice lack functional B and T cells and therefore
adaptive immunity, but do have normal innate immune cells
including antigen presenting cells, macrophages, and natural
killer cells (Custer et al., 1985). SCID mice have been used to
study virulence of intracellular bacterial pathogens including
phase I C. burnetii (Andoh et al., 2007). It was also recently
determined that a quantitative lethal dose 50 (LD50) could be
determined with NMII in SCID mice using longer experimental
periods (Islam et al., 2013) The most physiologically relevant
route of challenge would be aerosol, however, the disease
progression after IT challenge with NMII in SCID mice was
comparably slow and therefore not well-suited to large-scale
screening. Furthermore, the increase in splenomegaly and GEs
in organs was moderate, indicating a fundamental attenuation in
dissemination. It remains to be determined if a longer challenge
course (28–48 days) could produce a model of infection that
would accurately show dissemination from the lungs to spleen,
liver, and heart with splenomegaly, a hallmark of C. burnetii
challenge in mice. On the other hand, IP challenge of SCID
mice was dose-dependent for both bacterial loads in organs
and splenomegaly. In addition, higher bacterial loads produced
visible pathological changes in both the liver and heart of infected
animals. Using a dose of 1 × 106 GE per mouse, we determined
that severalHimar1mutant strains of C. burnetii were attenuated
for growth in SCIDmice. The observation that the T4SS-deficient
strain dotAwas attenuated in the SCIDmousemodel is consistent
with the previous finding that it does not replicate within host
cells.
A panel of Himar1 mutants that have previously published
intracellular replication phenotypes and/or defined mechanisms
of action were then tested for virulence in the SCID mouse
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 8 February 2017 | Volume 7 | Article 25
van Schaik et al. SCID Mouse Virulence Factors C. burnetii
model. Interestingly, the cvpB mutant was severely attenuated
during SCID mouse infection, yet has no replication defect in
tissue culture cells despite its unusual multivacuolar phenotype
(Newton et al., 2013; Martinez et al., 2016). CvpB is involved
in CCV development by interaction with phosphoinositides and
manipulating phosphatidylinsoitol 3-phosphate metabolism to
facilitate CCV biogenesis (Martinez et al., 2016). The phenotype
in SCID mice was even more severe than what was observed
in the G. mellonella challenge model, where cvpB had a 50%
reduction in mortality, confirming that proper CCV biogenesis is
essential for C. burnetii pathogenesis (Martinez et al., 2016). This
supports the hypothesis that the SCID mouse model can be used
to identify mutants that do not have intracellular growth defects
but are attenuated for virulence.
OmpA is an invasin that is necessary and sufficient for
C. burnetii to invade non-phagocytic cells (Martinez et al.,
2014). Like cvpB, it was previously determined that ompA
mutants had an attenuated phenotype compared to wild-type
NMII in G. mellonella (Martinez et al., 2014). This phenotype
was recapitulated in the SCID mouse model. The GE loads
and splenomegaly observed for ompA were significantly lower
than those observed for NMII, again validating the use of the
SCID mouse model to evaluate a range of attenuated virulence
phenotypes in NMII. Furthermore, tools unique to in vivo
infection models, such as FACs analysis could determine what
types of cells are infected with ompA to further dissect its role
in virulence in this animal model.
EnhC was the last potential virulence factor tested in the SCID
mouse model of infection. TheHimar1 enhCmutant was severely
attenuated in SCID mice as determined by GE in spleen and lack
of splenomegaly. There are several reasons that an enhC mutant
may be attenuated for growth in vivo. First, a previous report has
established that a C. burnetii enhCmutant had an internalization
defect, a phenotype that is also observed for enhCmutants in the
closely related bacterium Legionella pneumophila (Cirillo et al.,
2000; Weber et al., 2016). More recently, it was found that EnhC
of L. pneumophila inhibits the function of SltL transglycosylase
by interfering with peptidoglycan degradation, which benefits
intracellular replication by limiting the activation of host Nod1
by cell wall components (Liu et al., 2012). Each of these functions
could make significant contributions to virulence in vivo. In
addition, it was recently determined that enhC expression is up-
regulated during the transition to SCV in C. burnetii suggesting
it may have a role in cell-remodeling during phase transition
(Sandoz et al., 2016b). Any or all of these functions could cause
the severe attenuation phenotype we observed in SCID mice.
More research is necessary to resolve the function of C. burnetii
EnhC and its role in pathogenesis.
The ability to define relative fitness for C. burnetiimutants by
infection of SCID mice allows for an estimation of the fitness
cost of a mutation. This is an important step toward testing
pools of mutants in vivo, which will accelerate the identification
of novel virulence factors for C. burnetii. This advance, with
the advent of a novel Arg selection system for C. burnetii that
takes advantage of C. burnetii auxotrophic status for selection
in vitro and the Tn7 system for endogenous expression level
complementation should allow for the testing of Koch’s postulates
to define virulence factors (Beare et al., 2011b; Sandoz et al.,
2016a).
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